Hanna Tarhonskaya, Anthony Tumber, Akane Kawamura, Christopher J. Schofield
{"title":"In Vitro Enzyme Assays for JmjC-Domain-Containing Lysine Histone Demethylases (JmjC-KDMs)","authors":"Hanna Tarhonskaya, Anthony Tumber, Akane Kawamura, Christopher J. Schofield","doi":"10.1002/cpph.34","DOIUrl":null,"url":null,"abstract":"<p>Histone modifications, including lysine methylation marks on histone tails, modulate the accessibility of genes for transcription. Changes in histone tail methylation patterns can cause transcriptional activation or repression. The dynamic regulation of lysine methylation patterns is enabled by two distinct groups of enzymes: histone methyltransferases (KMTs) and demethylases (KDMs). The Jumonji C (JmjC) domain–containing lysine histone demethylases (JmjC-KDMs) alter the methylation levels of histone tails by removing tri-, di-, or mono-methylation marks. Because JmjC-KDMs activities are dysfunctional in cancer and other clinical conditions, they are targets for drug discovery. Efforts are underway to develop high-throughput assays capable of identifying selective, small-molecule inhibitors of KDMs. Detailed in this unit are protocols for mass spectrometry–based and formaldehyde dehydrogenase–coupled enzyme-based assays that can be used to identify inhibitors of JmjC-KDMs. © 2018 by John Wiley & Sons, Inc.</p>","PeriodicalId":10871,"journal":{"name":"Current Protocols in Pharmacology","volume":"80 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/cpph.34","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Protocols in Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cpph.34","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 3
Abstract
Histone modifications, including lysine methylation marks on histone tails, modulate the accessibility of genes for transcription. Changes in histone tail methylation patterns can cause transcriptional activation or repression. The dynamic regulation of lysine methylation patterns is enabled by two distinct groups of enzymes: histone methyltransferases (KMTs) and demethylases (KDMs). The Jumonji C (JmjC) domain–containing lysine histone demethylases (JmjC-KDMs) alter the methylation levels of histone tails by removing tri-, di-, or mono-methylation marks. Because JmjC-KDMs activities are dysfunctional in cancer and other clinical conditions, they are targets for drug discovery. Efforts are underway to develop high-throughput assays capable of identifying selective, small-molecule inhibitors of KDMs. Detailed in this unit are protocols for mass spectrometry–based and formaldehyde dehydrogenase–coupled enzyme-based assays that can be used to identify inhibitors of JmjC-KDMs. © 2018 by John Wiley & Sons, Inc.
含jmjc结构域赖氨酸组蛋白去甲基化酶(JmjC-KDMs)的体外酶分析
组蛋白修饰,包括组蛋白尾部的赖氨酸甲基化标记,调节基因转录的可及性。组蛋白尾部甲基化模式的改变可引起转录激活或抑制。赖氨酸甲基化模式的动态调节是由两组不同的酶实现的:组蛋白甲基转移酶(KMTs)和去甲基化酶(kdm)。Jumonji C (JmjC)结构域的赖氨酸组蛋白去甲基化酶(JmjC- kdm)通过去除三甲基化、二甲基化或单甲基化标记来改变组蛋白尾部的甲基化水平。由于jmjc - kdm在癌症和其他临床疾病中功能失调,因此它们是药物发现的靶点。人们正在努力开发能够识别kdm选择性小分子抑制剂的高通量测定方法。本单元详细介绍了基于质谱和甲醛脱氢酶偶联酶的检测方案,可用于鉴定jmjc - kdm的抑制剂。©2018 by John Wiley &儿子,Inc。
本文章由计算机程序翻译,如有差异,请以英文原文为准。